Mitapivat

– ENERGIZE is the First Study to Demonstrate Efficacy of an Oral Treatment for Non-Transfusion-Dependent Alpha- and Beta-Thalassemia – – Additional ENERGIZE Poster Presentation Highlights Improvements in Fatigue and Exercise Capacity in Patients Treated with Mitapivat Compared to Placebo – – Agios to Webcast Virtual Investor Event on June 16, 2024 at 10 a.m. Eastern Time or 4 p.m. Central European Summer Time – June 15, 2024 -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare diseases, today presented detailed results from the global Phase 3 ENERGIZE study of mitapivat in adults with non-transfusion-dependent (NTD) alpha- or beta-thalassemia in a plenary session (abstract #S104) at the European Hematology Association 2024 (EHA2024) Hybrid Congress, which is being held June 13-16, 2024, in Madrid, Spain. In a related poster presentation (abstract #P1529), the company presented additional data from the ENERGIZE study highlighting clinically meaningful improvements in health-related quality of life measures and patient-reported outcomes among patients in the mitapivat arm compared to those in the placebo arm. The ENERGIZE study achieved its primary endpoint, with mitapivat demonstrating a statistically significant increase in hemoglobin response rate compared to placebo. Statistical significance was also achieved for both key secondary endpoints associated with change from baseline in FACIT-Fatigue Score and hemoglobin concentration. These improvements were observed across all pre-specified subgroups. “The data from the ENERGIZE study are compelling, with mitapivat-treated patients achieving meaningful improvements in non-transfusion-dependent thalassemia’s hallmark symptom of anemia as well as in key measures of how patients feel and function,” said Sarah Gheuens, M.D., Ph.D., chief medical officer and head of R&D at Agios. “Together with the recently announced positive results from the ENERGIZE-T study of mitapivat in adults with transfusion-dependent thalassemia, the detailed ENERGIZE results underscore mitapivat’s potential to become an important treatment option for all subtypes of thalassemia – alpha- and beta-thalassemia, transfusion-dependent and non-transfusion-dependent – with the convenience of a pill. We look forward to working with regulators as we anticipate filing for approval in the U.S. by the end of this year.” “I am pleased to present the results of the ENERGIZE study to my esteemed colleagues and believe they will share my enthusiasm for the positive impact mitapivat may have for patients with non-transfusion-dependent alpha- or beta-thalassemia,” said Ali Taher, M.D., Ph.D., Professor of Medicine, Hematology & Oncology and Director – Naef K. Basile Cancer Institute, American University of Beirut Medical Center in Beirut, Lebanon; an investigator in the ENERGIZE study. “Globally, there are currently no approved oral treatments for non-transfusion-dependent thalassemia, which is characterized by anemia, ineffective erythropoiesis, hemolysis and iron overload and can cause severe complications, reduced quality of life and shortened lifespan. Based on the data collected in the ENERGIZE study, mitapivat has the potential to become a foundational treatment for non-transfusion-dependent thalassemia.” “The ENERGIZE data presented at this congress show that non-transfusion-dependent alpha- or beta-thalassemia patients treated with mitapivat experienced clinically meaningful improvements in fatigue and walking capacity, as well as improvements in patient-reported outcomes across a range of disease symptoms,” said Kevin Kuo, M.D., MSc, FRCPC; Division of Hematology, University of Toronto in Ontario, Canada; an investigator in the ENERGIZE study. “There is a tremendous need for oral therapies that can improve how people with thalassemia feel and function and reduce the impact of the disease on their lives. Patients with alpha- or beta-thalassemia, regardless of transfusion status, frequently report negative effects on daily activities and physical functioning. On a number of domains of health-related quality of life, adults with non-transfusion-dependent thalassemia experience even greater symptom burden than their transfusion-dependent counterparts. I am excited about the potential of mitapivat to support quality of life improvements for these individuals.” Agios also recently announced positive results from the Phase 3 ENERGIZE-T study of mitapivat in adults with transfusion-dependent alpha- or beta-thalassemia. The company intends to file for regulatory approval of mitapivat as a treatment for thalassemia by the end of 2024, incorporating all available data from both studies. A total of 194 patients were enrolled in the study, with 130 randomized to mitapivat 100 mg twice-daily (BID) and 64 randomized to matched placebo. 122 (93.8%) in the mitapivat arm and 62 (96.9%) in the placebo arm completed the 24-week double-blind period of the study. Baseline demographics and characteristics were balanced between mitapivat and placebo arms, and representative of a population of non-transfusion dependent thalassemia patients. The study met the primary endpoint of hemoglobin response. Hemoglobin response was defined as an increase of ≥1 g/dL in average hemoglobin concentrations from week 12 through week 24 compared with baseline. 42.3% (n=55/130) of patients in the mitapivat arm achieved a hemoglobin response, compared to 1.6% (n=1/64) of patients in the placebo arm (2-sided p Among patients who achieved hemoglobin response in the mitapivat arm, the mean change from baseline in average hemoglobin concentration from week 12 to 24 was 1.56 g/dL. Hemoglobin response rates were higher among those treated with mitapivat compared to placebo across all prespecified subgroups, including: Thalassemia genotype: 23.8% (n=10/42) of alpha-thalassemia patients in the mitapivat arm achieved a hemoglobin response, compared to no alpha-thalassemia patients in the placebo arm. 51.1% (n=45/88) of beta-thalassemia patients in the mitapivat arm achieved a hemoglobin response, compared to 2.3% (n=1/44) of beta-thalassemia patients in the placebo arm. Baseline hemoglobin concentration: 47.4% (n=45/95) of patients whose baseline hemoglobin concentration was ≤9.0 g/dL in the mitapivat arm achieved a hemoglobin response, compared to 2.1% (n=1/47) of patients in the placebo arm. 28.6% (n=10/35) of patients whose baseline hemoglobin concentration was between 9.1 and 10.0 g/dL achieved a hemoglobin response, compared to no patients in the placebo arm. Treatment with mitapivat also demonstrated statistically significant improvements compared to placebo for both key secondary endpoints: The average change from baseline (95% confidence interval) in FACIT-Fatigue (Functional Assessment of Chronic Illness Therapy-Fatigue) subscale score from week 12 to week 24 was 4.85 (3.41, 6.30) in the mitapivat arm compared to 1.46 (–0.43, 3.34) in the placebo arm (p=0.0026). The average change from baseline (95% confidence interval) in average hemoglobin concentration from week 12 to week 24 was 0.86 (0.73, 0.99) g/dL in the mitapivat arm compared to –0.11 (–0.28, 0.07) g/dL in the placebo arm (p<0.0001). Improvements were observed in patients treated with mitapivat across measures of health-related quality-of-life, including the six-minute walk test and the Patient Global Impression of Change (PGIC) fatigue, walking capacity, and thalassemia symptoms subscales. Six-minute walk test: The average change (95% confidence interval) from baseline to week 24 was 30.48 (19.31, 41.64) meters in the mitapivat arm compared to 7.11 (–7.39, 21.62) in the placebo arm. PGIC: A higher proportion of patients in the mitapivat arm reported improvements in fatigue as per PGIC versus those in the placebo arm at weeks 12, 16, 20, and 24. A higher proportion of patients in the mitapivat arm reported improvements in thalassemia symptoms and walking capacity as per PGIC at week 24 versus those in the placebo arm. Overall, during the 24-week double-blind period, incidence of adverse events was similar across mitapivat and placebo arms, with 82.9% (n=107) of patients in the mitapivat arm and 79.4% (n=50) of patients in the placebo arm experiencing treatment-emergent adverse events (TEAEs). The most frequently reported TEAEs were headache, initial insomnia, nausea and upper respiratory tract infection. 3.9% (n=5) of patients in the mitapivat arm experienced Grade ≥3 treatment-related TEAEs. There were no serious TEAEs. 3.1% (n=4) of patients in the mitapivat arm experienced TEAEs leading to discontinuation; there were no TEAEs leading to discontinuation in the placebo arm. PYRUKYND is a pyruvate kinase activator indicated for the treatment of hemolytic anemia in adults with pyruvate kinase (PK) deficiency in the United States, and for the treatment of PK deficiency in adult patients in the European Union. Agios is the pioneering leader in PK activation and is dedicated to developing and delivering transformative therapies for patients living with rare diseases. In the U.S., Agios markets a first-in-class pyruvate kinase (PK) activator for adults with PK deficiency, the first disease-modifying therapy for this rare, lifelong, debilitating hemolytic anemia. Building on the company's deep scientific expertise in classical hematology and leadership in the field of cellular metabolism and rare hematologic diseases, Agios is advancing a robust clinical pipeline of investigational medicines with programs in alpha- and beta-thalassemia, sickle cell disease, pediatric PK deficiency and MDS-associated anemia. In addition to its clinical pipeline, Agios is advancing a preclinical TMPRSS6 siRNA as a potential treatment for polycythemia vera, and a preclinical PAH stabilizer as a potential treatment for phenylketonuria (PKU). For more information, please visit the company’s website at www.agios.com. The content above comes from the network. if any infringement, please contact us to modify.

点击蓝字 关注我们 本周，最大的热点就是2024年美国临床肿瘤学会（ASCO）年会了，国内外巨头都公布了不少重磅药的最新临床研究结果。我们先来看审评审批方面，并没有重磅创新药上市，但有不少药拟被纳入突破性疗法，且艾尔建注射用A型肉毒毒素首次获批咬肌适应症；其次是研发方面，由于ASCO年会，因此有不少药公布了最新进展，比如恒瑞的PD-单抗卡瑞利珠单抗、传奇生物的西达基奥仑赛等均公布最新研究结果；然后是交易及投融资方面，交易不多，但祥根生物与丽珠医药就1类抗真菌新药SG1001签署大中华区许可协议这值得一提；最后是上市方面，Telix Pharmaceuticals已申请在美国纳斯达克进行IPO。 本期盘点包括审评审批、研发、交易及投融资和上市四大板块，统计时间为6.3-6.7，包含26条信息。  审评审批 NMPA 上市 批准 1、6月3日，NMPA官网显示，艾尔建（Allergan）的注射用A型肉毒毒素（商品名：保妥适）新适应症获批，用于暂时性改善成人显著或非常显著的咬肌突出（肥大）。该产品获批用于暂时性改善成人显著或非常显著的咬肌突出（肥大），中国是保妥适在全球首个获批该适应症的市场。 申请 2、6月3日，CDE官网显示，罗氏的一款口服、高选择性PI3Kα抑制剂伊那利塞片（Inavolisib）申报上市，用于联合哌柏西利和氟维司群治疗既往接受内分泌疗法辅助治疗后或完成辅助内分泌治疗后12个月内复发的PIK3CA突变、激素受体阳性（HR+）、人表皮生长因子受体2阴性（HER2-）的局部晚期或转移性乳腺癌成人患者。罗氏已向FDA递交该药上市申请。 3、6月3日，CDE官网显示，艾伯维的利生奇珠单抗（risankizumab，Skyrizi）注射液及其皮下注射剂型新适应症申报上市。Skyrizi是一种白细胞介素-23（IL-23）抑制剂，2023年7月，利生奇珠单抗首次在中国申报上市，推测适应症为克罗恩病，目前正在审评中。 4、6月7日，CDE官网显示，康诺亚的1类新药司普奇拜单抗注射液（CM310）申报上市，用于治疗慢性鼻窦炎伴鼻息肉（CRSwNP）。司普奇拜单抗通过靶向IL-4Rα，可双重阻断白介素4（IL-4）及白介素13（IL-13）的信号传导，而IL-4及IL-13为引发2型炎症的两种关键细胞因子。 临床 批准        5、6月5日，CDE官网显示，赛诺菲（Sanofi）的婴幼儿鼻喷呼吸道合胞病毒减毒活疫苗（SP0125）获批临床。SP0125是一款被设计用于预防呼吸道合胞病毒（RSV）引起疾病的婴幼儿疫苗，可为6至24月龄的婴幼儿提供保护。 6、6月6日，CDE官网显示，加科思1类新药JAB-30355片获批临床，拟开发用于携带TP53 Y220C突变的晚期实体瘤。JAB-30355是加科思自主研发的一种用于治疗携带P53 Y220C突变的局部晚期或转移性实体瘤患者的口服生物活性小分子激活剂，目前正在美国进行针对晚期实体瘤患者的Ⅰ/Ⅱa期临床研究。 优先审评 7、6月3日，CDE官网显示，诺诚健华的CD19单抗注射用坦昔妥单抗（tafasitamab）拟纳入优先审评，联合来那度胺用于治疗复发或难治性且不适合自体干细胞移植（ASCT）的弥漫性大B细胞淋巴瘤（DLBCL）的成人患者。 突破性疗法 8、6月4日，CDE官网显示，中因科技的ZVS101e注射液拟纳入突破性治疗品种，用于治疗结晶样视网膜变性。ZVS101e是中因科技开发的一款基因替代治疗药物，此前已获美国FDA授予孤儿药资格，并在中国和美国获得IND批件。目前该药物已完成Ⅰ/Ⅱ期临床试验，即将进入Ⅲ期临床试验阶段。 9、6月4日，CDE官网显示，艾伯维（AbbVie）的输注用无菌冻干粉telisotuzumab vedotin拟纳入突破性治疗品种，拟用于治疗在铂类药物治疗期间或治疗后发生疾病进展的c-Met蛋白高表达、晚期/转移性EGFR野生型非鳞状非小细胞肺癌（NSCLC）患者。telisotuzumab vedotin（Teliso-V）是艾伯维在研的一款靶向c-Met的抗体偶联药物（ADC）。 10、6月4日，CDE官网显示，勃林格殷格翰（Boehringer Ingelheim）的BI 456906注射液拟纳入突破性治疗品种，拟用于治疗代谢功能障碍相关脂肪性肝炎（MASH）。这是由勃林格殷格翰和Zealand公司联合开发的GLP-1受体和胰高血糖素（GCG）受体双重激动剂。 11、6月6日，CDE官网显示，恒瑞医药的注射用SHR-A1811拟纳入突破性治疗品种，用于既往接受过一种或一种以上治疗方案的HER2阳性不可切除或转移性胆道癌。注射用SHR-A1811是一款靶向HER2的抗体偶联药物（ADC），这也是SHR-A1811第6次拟纳入突破性治疗品种。 12、6月7日，CDE官网显示，拜耳（Bayer）的BAY2927088溶液拟纳入突破性治疗品种，用于治疗携带HER2（ERBB2）激活突变且既往接受过一种全身性治疗的不可切除或转移性非小细胞肺癌（NSCLC）成人患者，此适应症于2024年2月获FDA授予突破性疗法认定。BAY2927088是一种口服、可逆酪氨酸激酶抑制剂（TKI）。 FDA 临床 批准 13、6月5日，FDA官网显示，康朴生物的KPG-121获批Ⅱ/Ⅲ期临床，联合阿比特龙用于一线治疗转移性去势抵抗性前列腺癌（mCRPC）。KPG-121是新一代CRBN E3泛素连接酶复合物（CRL4-CRBN）调节剂，具有抑制细胞增殖和抗血管生成活性，以及增强免疫调节功能。 研发 临床状态 14、6月3日，药物临床试验登记与信息公示平台显示，宜明昂科的替达派西普启动Ⅲ期临床试验，旨在评估替达派西普（2.0mg/kg，每周1次）联合替雷利珠单抗（200mg，每3周1次）对比研究者选择的化疗方案（苯达莫司汀+吉西他滨）治疗抗PD-(L)1单抗难治性经典型霍奇金淋巴瘤（cHL）患者的疗效和安全性。替达派西普成为全球首款进入Ⅲ期阶段的SIRPα靶向药物。 临床数据 15、6月3日，传奇生物公布了西达基奥仑赛（CARVYKTI）针对多发性骨髓瘤患者的Ⅱ期研究CARTITUDE-2队列D的结果。数据显示，在前线治疗自体干细胞移植后未达到完全缓解（CR）的患者在单次输注西达基奥仑赛联合或不联合来那度胺维持治疗后，可获得深度持久的缓解，总缓解率（ORR）达94%。西达基奥仑赛是一种靶向B细胞成熟抗原（BCMA）的CAR-T。 16、6月3日，康诺亚公布了1类新药司普奇拜单抗（CM310）用于治疗成人中重度特应性皮炎的Ⅲ期临床研究长期疗效及安全性数据。52周研究结果显示，司普奇拜单抗在中重度特应性皮炎成人患者长期治疗中可产生持续的临床获益，且安全性良好。司普奇拜单抗是一种针对IL-4Rα的高效、人源化抗体，为我国首个自主研发并申请上市的IL-4Rα抗体药物。 17、6月3日，应世生物公布了全球首创FAK抑制剂Ifebemtinib（IN10018）联合KRAS G12C抑制剂Garsorasib（D-1553）针对KRAS G12C突变非小细胞肺癌（NSCLC）一线治疗的Ib/II期临床显著获益数据，结果显示该双口服/去化疗联合治疗方案可显著提高一线KRAS G12C突变NSCLC患者的疗效应答。 18、6月3日，硕迪生物公布了小分子GLP-1受体激动剂GSBR-1290治疗肥胖症的Ⅱa期研究以及胶囊和片剂PK研究均取得了积极结果。结果显示，经安慰剂校正后GSBR-1290治疗组患者体重下降幅度具有临床意义和统计学意义，12周时下降6.2%（p<0.0001）。第12周时，GSBR-1290组有67%患者体重减重≥6%，33%患者体重减轻≥10%，而安慰剂组这一比例为0%。 19、6月3日，Agios公布了mitapivat用于输血依赖性（TD）α或β地中海贫血成人患者的Ⅲ期ENERGIZE-T研究达到主要终点，能够显著减少输血。Mitapivat是一款first-in-class新型、口服丙酮酸激酶-R（PKR）激活剂，2022年2月，mitapivat首次获FDA批准上市，用于治疗丙酮酸激酶（PK）缺乏引起的成人溶血性贫血。 20、6月4日，西比曼公布了C-CAR031在经过多线治疗的晚期肝癌（HCC）患者中（先前接受过1-6线治疗）中可控的安全性和令人鼓舞的抗肿瘤活性。在中位随访9.03个月时，在所有剂量水平（DLs）的患者中实现了91.3%的疾病控制率（DCR）和56.5%的客观缓解率（ORR），在DL4的患者中，ORR为75.0%。C-CAR031为一款新型GPC3靶向CAR-T。 21、6月5日，亚盛医药公布了奥雷巴替尼（HQP1351）在TKI耐药的琥珀酸脱氢酶缺陷型（SDH-）胃肠道间质瘤（GIST）患者中的最新数据。数据显示，患者的临床获益率达92.3%。奥雷巴替尼是亚盛医药开发的一款口服第三代BCR-ABL抑制剂，目前已有两项适应症获批上市。 22、6月5日，恒瑞医药公布了抗PD-1单抗卡瑞利珠单抗单药辅助治疗高危局部晚期鼻咽癌的开放标签、随机、对照、Ⅲ期临床研究（DIPPER研究）结果。随访结果显示，相较对照组，辅助阶段使用卡瑞利珠单抗可以显著改善患者的EFS，达到了主要研究终点：试验组和对照组3年EFS率分别为86.9%和77.3%。 23、6月6日，中国生物制药公布了CD137/PD-L1双抗FS222治疗晚期实体肿瘤Ⅰ期临床研究结果。研究中所有患者的疾病控制率（定义为完全缓解率、部分缓解率和疾病稳定率的总和）为45.0%。在19例既往接受过PD-1抗体治疗的转移性/晚期皮肤黑色素瘤患者中，总缓解率（定义为完全缓解和部分缓解比例之和）为47.4%，疾病控制率为68.4%。 交易及投融资 24、6月4日，祥根生物与丽珠医药联合宣布，双方就1类新药SG1001达成战略合作并签署大中华区权益交易协议。根据协议，丽珠医药将获得SG1001在大中华区（包括中国大陆、中国澳门、中国香港和中国台湾地区）用于抗真菌等治疗领域所有可开发剂型和适应症的独家研发、生产及商业化权益，祥根生物将保留SG1001在合作区域外的研发、生产及商业化的权益。 25、6月6日，GSK宣布，以高达5000万美元（约3900万英镑）的价格收购了Elsie。此次收购使GSK整合了Elsie的寡核苷酸发现、合成和递送技术，以增强自身平台的研发能力。在此之前，GSK曾于2023年7月与Elsie达成过研究合作。 上市 26、6月5日，Telix Pharmaceuticals公司已申请在美国纳斯达克进行IPO，计划通过发行股票筹集2亿美元。Telix是一家专注于治疗和诊断放射性药物的医药公司，2020年11月，远大医药曾与Telix公司达成总价不高于2.5亿美元的合作，引入后者6款放射性核素偶联药物并认购其7.6%股份。目前该6款产品已经在中国进入不同的临床研究阶段。 【企业推荐】 【智药研习社直播预告】 来源：CPHI制药在线 声明：本文仅代表作者观点，并不代表制药在线立场。本网站内容仅出于传递更多信息之目的。如需转载，请务必注明文章来源和作者。 投稿邮箱：Kelly.Xiao@imsinoexpo.com ▼更多制药资讯，请关注CPHI制药在线▼ 点击阅读原文，进入智药研习社~